Navigation Links
Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302

Third PharmacoSurgery(TM) Platform Product Candidate in Clinical Trials

SEATTLE, Sept. 9 /PRNewswire/ -- Omeros Corporation today announced that it is enrolling patients in a Phase 1/Phase 2 study of OMS302, the Company's third PharmacoSurgery(TM) product candidate, for use during ophthalmologic surgery. At least 60 patients undergoing age-related cataract extraction with lens replacement are planned for enrollment in the study.

"With the initiation of this study, all three of Omeros' current PharmacoSurgery product candidates are now in the clinic," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "Each of the two agents in OMS302 is currently used individually and perioperatively during eye surgery. OMS302 combines these two agents and their pharmacologic activities into a single proprietary product candidate. With approximately three million cataract procedures performed annually in the U.S. alone, OMS302 is designed to address a large and growing market."

The Phase 1/Phase 2 trial is a randomized, double-blind, vehicle-controlled and parallel-assigned study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain, discomfort and inflammation following the procedure. OMS302 is added to standard irrigation solutions used in ophthalmologic surgery and is delivered directly to the eye during the operation.

PharmacoSurgery(TM) product candidates are proprietary combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. The lead product candidate in the PharmacoSurgery(TM) platform is OMS103HP, which is currently in two Phase 3 clinical programs evaluating its safety and ability to improve postoperative joint function and reduce pain following arthroscopic surgery. The urological PharmacoSurgery(TM) product candidate OMS201, currently in a fully enrolled Phase 1 clinical study, is designed to inhibit surgically induced inflammation, pain and smooth muscle spasm, thereby facilitating uroendoscopy and reducing postoperative frequency, urgency and discomfort.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of pre-clinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at

SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
2. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
3. CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
4. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
5. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
8. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
(Date:11/30/2015)... KIRKLAND, Wash. , Nov. 30, 2015 /PRNewswire/ ... of Post-Processing services, is pleased to announce a ... of medical imaging services. Building on its ISO-9001:2008 ... adopted and implemented comprehensive Core Lab protocols and ... wide variety of research activities.  Their Core Lab ...
(Date:11/30/2015)... 30, 2015 Mexico Healthcare and Life Sciences ... Report 2015 . --> Pharmaboardroom releases its new 98-page ... Latin America , a country of over 122 million ... of over 122 million people. --> It offers companies, ... life sciences insights into the second largest pharma and healthcare market ...
(Date:11/30/2015)... , November 30, 2015 Elbit ... the "Company") announced today that it was informed by InSightec ... Drug Safety (MFDS) has approved its Exablate Neuro system ... --> --> Insightec,s Exablate Neuro ... alternative that combines two technologies: Focused Ultrasound, which is ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... The Foundation for Breast and Prostate Health (FBPH)—a ... with the award-winning creator and writer of Downton Abbey Julian Fellowes to host ... Union League of Philadelphia. , The benefit, titled “An Evening with Julian ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... Specialty Ingredients (ASI) as their exclusive channel partner for the Nutraceutical Specialties products ... markets in the US, effective immediately. , “We are pleased to announce ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i Systems, a ... today that Michigan-based Family Health Center (FHC) has selected i2iTracks as their population ... was awarded the largest Affordable Care Act grant for Federally Qualified Health Centers ...
(Date:11/30/2015)... PITTSBURGH, PA (PRWEB) , ... November 30, 2015 , ... ... quality of life in the womb. "My last baby had high blood pressure due ... way for mothers to protect their babies from noise pollution as well as radio ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy ... a top ophthalmologist on Long Island’s east end. During the broadcast, entitled “Eyes: the ... and treatment of glaucoma and cataracts, and how a visit with his grandmother to ...
Breaking Medicine News(10 mins):